Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib binimetinib cetuximab for the treatment of BRAFV600Emutant metastatic colorectal cancer

Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer

05:04 EDT 6 Jul 2019 | Biotech 365

– Encorafenib combinations (encorafenib + binimetinib + cetuximab together = encorafenib Triplet; encorafenib + cetuximab together = encorafenib Doublet) showed statistically significant improvement in OS and ORR versus control – – Data support potential to be the first chemotherapy-free, targeted … Continue reading →

More From BioPortfolio on "Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer"